

Annual Report 2010

Antibiotice continued its sustainable development in 2010.

Thus, the company obtained a turnover of 243.63 million lei, up 11% compared with 2009. Gross profit in 2010 amounts to 18.47 million lei, 18 percent higher compared with the previous year. The product portfolio was enriched by 6 new drugs and 13 Marketing Authorizations were obtained for as many pharmaceutical products.

The activity on foreign markets was enhanced, in 2010 Antibiotice managing its first export of finished products on the U.S. market. The turnover generated by sales on foreign markets (55 countries) increased by 35% in 2010 against 2009.

On the domestic market, the company recorded a sales increase of 8%, ranking the 4th in the top of OTC and generic producers in Romania.